HMG-CoA reductase / PPAR-alpha

Class

Statin + fibrate fixed-dose combination

This mechanism combines two lipid-lowering strategies that act on different steps of fat and cholesterol metabolism. HMG-CoA reductase is the rate-limiting enzyme in the liver's pathway for making cholesterol; inhibiting it (the statin component) reduces internal cholesterol production, prompting liver cells to pull more low-density lipoprotein (LDL, the so-called 'bad cholesterol') out of the bloodstream. PPAR-alpha is a nuclear receptor that, when activated (the fibrate component), turns on genes governing fatty acid breakdown and processing of triglyceride-rich particles, lowering triglycerides and modestly raising high-density lipoprotein (HDL). Individually, statins are most effective against elevated LDL, while fibrates are most effective against elevated triglycerides and low HDL. Many patients, particularly those with metabolic syndrome or diabetes, have a mixed lipid abnormality involving both elevated LDL or triglycerides and low HDL, which neither drug class fully addresses alone. Pairing the two mechanisms in a fixed-dose combination aims to correct multiple abnormalities in the lipid profile simultaneously, which is relevant to reducing cardiovascular risk broadly across atherosclerotic disease. This dual approach reflects a general principle in cardiometabolic pharmacology: complementary pathways are combined when a single target cannot correct all components of a disturbed lipid pattern.